Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In terms of why I think our pending recall of loaned shares will cause a more significant short squeeze than our first one did, I listed the LIVE-AIR, PREACH-M, RATinG, and the Mayo Clinic-sponsored trial in CAR-T, that could lead to the authorization or approval of lenz. Those were the trials Humanigen highlighted in their last 10-Q. Success in those trials could entice sustained buying interest in Humanigen's stock.
But management also mentioned partnerships and a possible business combination, without going into further detail. I have voiced my opinion that Novavax may be a candidate for a relationship with Humanigen, and noted the covid opportunity for both companies working together.
"Novavax is projecting 30-35M covid vaccinations in the US this 2023-2024 period.
see slide 17
https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/tm242356d1_ex99-1.htm
If lenz is used as an adjuvant, or is used to enhance Novavax's Matrix-M saponin compound, that would greatly expand the market for lenz as a prophylaxis. But, if lenz is also used in the Combined Influenza Covid (CIC) vaccine, for which they have outlined a faster path forward in bringing to market (slide 14), then that could open a huge new market for lenz."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173606511
But in addition for lenz to be used as a covid therapeutic, a covid prophylaxis, a CMML preventative, and to enhance bone marrow transplant, and CAR-T enhancement, Novavax mentions the following in regards to their effort to fight malaria.
Malaria "Kills 630,000 people/year, incl ~ 1,300 children/day."
see slide 12 of their presentation linked above.
Is this an additional opportunity for lenz? It seems to me that it is.
"Cytokine-modulating strategies may represent a promising modern approach in disease management. In this review, we discuss the host immune response in malaria, analyzing the latest studies on the roles of pro- and anti-inflammatory cytokines."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592744/
I have a long-standing, pro-Novavax bias. But it seems to me that the synergies of these two companies working together hold fantastic potential.
Hi, eb,
Before I forget, I'm sorry I failed to mention covid pneumonia, instead of recent posts where I mentioned just covid. It was not intentional.
Also, thank you for recognizing a degree of plausibility in my assessment of the company's outlook, which is about 180 degrees opposite of Yooo's.
I try to provide the reasons for my opinions by linking the source data. But until the events unfold as I anticipate, I prefer that people have the full spectrum of opinion, and Yooo's posts always provide an opposite view. I find some utility in that.
I don't have access to any private boards, if they are still active. This board is the most active, and Yooo helps to make that true. That's the only affinity I have for him. I expect that there will be a sharp increase in interest from prospective investors in the near term, or at some time, and this board might be useful to them for historical perspective.
Must be true, cause I have no idea what's inspiring your little crusade.
There must be some point to these posts about IR that's gotten you excited. IR seemed to be one of the hats Ed Jordan was wearing until he resigned in September. The company cut staff and contractors, and people are still complaining about salaries being paid. You can't expect business as normal under these circumstances.
Oh my God, four exclamation points! I don't like to use the phone. I don't call anybody.
I emailed IR a few years ago, before the phone call. I got a response from Durrant when I was using their website regarding compassionate use for a friend. I don't have other emails or phone calls from anyone connected to Humanigen, directly or indirectly.
I'm not trying to salt wounds, Yooo. I'm only sincerely trying to assemble the pieces as they are played. I won't be stopping that.
Just because I haven't been proven correct yet...doesn't mean that I have not been right all along. Sorry about the double negative. I know it's hard enough for you to understand already.
Private Messager,
I hadn't noticed the correlation you mentioned. The attempt to flood our message board is intended to distract attention from our progress, so I kind of have Moderna blocked. But when posters here reply to him, I see the post to which they're replying, and I agree with some of his postings regarding the government's unethical role in controlling market access. So I guess it's accurate to say that I have 0.5 persons blocked.
What I did notice though, in your case, was yet another demonstration of the consideration Humanigen has for their shareholders. Whether that was manifested as it was in your case, or by calling me at about 7:30am on the day our EUA was Declined (I sent them a brief note, and the call I got in reply was after the caller had spent the entire night calling foreign investors), or whether that consideration for shareholders is shown by managements' personal involvement in getting the compassionate use of lenz to patient-shareholders, these things demonstrate the character of our management team. I think even their first effort to get a drug to market (it might have been HGEN005) for Chagas Disease, was a compassionate effort to treat a small segment of the world's population, that was totally neglected by Big Pharma.
I hope management achieves all the success they and Humanigen deserve. The world will be a better place, if they do.
Pretty good overview of the ADC market, which I think is relevant to our product pipeline. This sheds some light on 'what's next' for Humanigen.
https://www.marketsandmarkets.com/Market-Reports/antibody-drug-conjugates-market-122857391.html?gad_source=1&gclid=EAIaIQobChMI_-WmxpndgwMV6ROtBh1ysQd4EAAYASAAEgIIIvD_BwE
One thing to note is that Taran entered into an Asset Purchase Agreement with Humanigen, not a Buy Out, to include our pipeline products, the equity in one of our subsidiaries, and "certain causes of action." The main cause of action I want to see is the recall of our loaned shares. Humanigen will do nothing that would eliminate those shares until the short positions have been bought-in. That transaction could leave a substantial amount of cash on the balance sheet, following the resolution of the bankruptcy. It could certainly be enough in value to meet Nasdaq Listing Standards for a number of interested entities.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465924000421/o152468k.htm
Such interested entities could include some of whom we may have engaged, such as Baudax/TeraImmune, Novavax, Gracell, and possibly AstraZeneca.
Our own interest, especially if Taran's purchased subsidiary survives as the Parent company of Humanigen, might best be served in Australia.
"Expansion of the PREACH-M study is a critical next step in our realignment strategy. Associate Professor Thomas is a world expert in CMML and program leader for Blood Cancers at SAHMRI. SAHMRI is a leader in precision medicine that assists patients in finding the proper treatment for their cancer," commented Cameron Durrant, Chairman and CEO of Humanigen. "Lenzilumab was discovered in Australia, so it is only fitting that we leverage the wealth of local knowledge that exists for lenzilumab as we continue clinical development. Expanding the number of sites may accelerate enrollment. We anticipate seeing preliminary results from this study in the first half of 2023."
https://ir.humanigen.com/English/news/news-details/2022/Humanigen-and-SAHMRI-Announce-Expansion-of-the-PREACH-M-Study-of-Lenzilumab-in-CMML/default.aspx
Further, we now know the interim results of the PREACH-M study have been phenomenal.
"Humanigen and the Principal Investigator are assessing regulatory pathways that may enable
early results to support a regulatory submission and potential approval by the Therapeutic Goods Administration in
Australia, which could be expanded through Project Orbis10 to the United States and the United Kingdom."
https://s28.q4cdn.com/539885110/files/doc_news/Humanigen-Presents-Promising-New-Hematologic-Data-from-PREACH-M-Trial-for-Chronic-Myelomonocytic-Leukemia-Treatment-at-the-2023-Europ-OYZCQ.pdf
I think things could come together for us very quickly now, and we could have positive regulatory and structural developments to report, to coincide with, and support, the recall of our loaned shares.
"COVID levels are up to 19 times higher than reported, WHO says as it warns of the potential dangers of repeat reinfection: ‘We don’t know everything about this virus’
Erin Prater
Fri, January 12, 2024...
COVID hospitalizations and ICU admissions rose by 42% and 62%, respectively, in December."
https://www.yahoo.com/finance/news/covid-levels-19-times-higher-155149181.html
What is the covid reinfection rate for lenz-treated patients, I ask for the (100th? 1,000th?) time? Is there a study on-going by a Humanigen partner based on the increased ICU utilization and deaths rates?
No, I don't believe, "...that Cam can pull a short squeeze slaughter over on these funds, again after they were burned once"
I believe Dale and Durrant WILL pull off an even bigger short squeeze than before. In fact, I have no doubt about it.
"Universal coronavirus vaccine may save lives, money in future pandemic
Dennis Thompson, HealthDay News
Fri, January 12, 2024
A universal coronavirus vaccine could have saved millions of lives and billions of dollars if one had been available prior to the pandemic, a new study argues.
Further, a universal vaccine -- one that targets parts of the virus common to all coronaviruses -- could still be a game-changer in the future, researchers say.
But that's only possible if one is developed before another variant mutates and runs rampant through the human population..."
https://www.yahoo.com/news/universal-coronavirus-vaccine-may-save-173805468.html
Lenzilumab.
I should note that Gracell filed a 6-K, also on Jan 8th, which was designated as the Record Date for shareholders who will be able to vote on the merger with AstraZeneca.
I think that much like GSK, AstraZeneca offers significant synergy for Humanigen to consider, if they aren't already.
https://www.astrazeneca.com/partnering/our-areas-of-partnering-interest.html#!
The only other SEC filings I monitor is for Baudax. We know we/Dale bought 500K shares of Baudax at the end of Q2, when they acquired TeraImmune, which I think was our focus of making the purchase.
No, I don't believe that expert traders comprise those holding short positions here. I believe just the opposite, that smart traders are long.
The REAL experts are Dale and Durrant, who provided the loaned shares, and are about to recall those loaned shares.
And by the way, you don't need to be an expert to buy. You just generally can't be a US-domiciled American.
And by the way:
MLK Day, as the holiday is often called, was made a federal holiday in 1983 and was first observed in 1986. The holiday is always celebrated on the third Monday in January, which this year falls on King's actual birthday. Here's what you can expect. U.S. stock exchanges will be closed Monday.
https://www.morningstar.com/news/marketwatch/20240112332/is-the-stock-market-open-on-mlk-day-will-the-post-office-deliver-mail
You will never get it, will you?
Transferring shares between the nominee and the beneficial owner accounts will be reflected as buys and sells. You, and the financial reporting industry, can't take the Form 4's at face value.
Good!! Now explain the design of the share structure and how Humanigen could be holding 92% of the shares they have issued.
I "get" the design of the share structure, which completely obliterates your dull assessment of how management has enriched themselves. How did Humanigen accumulate 110M of the 119M shares they issued?
The failure of the FDA to award our EUA, despite a Hazard Ratio of 2.54, according to the Thorax peer review, is the reason we can't take lenz as the covid standard of care.
Why can't you understand that?
We'll get lenz authorization and approval. How many millions of preventable deaths will be suffered until then is the question.
"These COVID Symptoms Are Red Flags That You Need Medical Attention
Jillian Wilson
Fri, January 12, 2024
Breathing issues, high fever, dizziness and confusion are all reasons to get immediate medical care."
https://www.yahoo.com/news/covid-symptoms-red-flags-medical-104514298.html
I agree that the move to the expert market was by design, and intended to decrease visibility of the on-going corporate actions, in part.
BUT THAT'S FOR OUR BENEFIT.
Our float could very well be 192% of our OS, and management is about to recall our loaned shares. We have become invincible to the market manipulation of our share price. Shorts will have to meet the share price management will demand, which I hope will start at $201. We have never been stronger!!!
How are we represented now, as it relates to the value of our patents?
Durrant intends to keep the share structure intact through the bankruptcy and merger(s).
I recognize that we disagree.
That would be appreciated, Private Messager.
But I'm not surprised about the optics. In fact, I think they support my position, rather than disprove it. There's lots of talk about a concentration of shares at the 100M share level now. How long have I been talking about the company holding 110M of their own shares? The named brokerages with 100M+ shares are likely to become our biggest purchasers, because I think they will have to buy-in their clients' short positions. And how long have I been talking about a merger? How might that relate to what we're seeing about Taran buying the assets of one of our subsidiaries? Is that setting the stage for a parent-subsidiary downstream merger?
I'm just enjoying the show, and trying to learn, as I try to piece together the parts being assembled. I may never have another learning opportunity like this one.
I'm seeing no sign of a course change from the pathway I believe we are taking.
Who said anything about taking the company private? Maybe I missed something, because I'm largely ignoring this whole bankruptcy proceeding. But I do believe that this voluntary CH11 filing makes us much stronger than an involuntary CH7 that could have been filed by creditors.
Those brokers don't appear to be holding proprietary accounts, do they?
Novavax is projecting 30-35M covid vaccinations in the US this 2023-2024 period.
see slide 17
https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/tm242356d1_ex99-1.htm
If lenz is used as an adjuvant, or is used to enhance Novavax's Matrix-M saponin compound, that would greatly expand the market for lenz as a prophylaxis. But, if lenz is also used in the Combined Influenza Covid (CIC) vaccine, for which they have outlined a faster path forward in bringing to market (slide 14), then that could open a huge new market for lenz.
But, I actually agree with some of what he said today.
Private Messager, that was an astounding revelation!! Just remember our history. I think our past is about to become prologue...Breathe...
"Somebody still owns over 100 million shares? where is it?"
Can't say for sure where the shares are now, but, "...I think the company could be holding 110M of the 119M shares in our OS. The float could be 192% of our OS."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173563290 (Plus about 100 other of my posts over the years)
I wouldn't go looking for them, though. They'll be on their way back to Humanigen, the beneficial owner, once the company recalls their loaned shares.
I was hoping that somebody would respond to your questions about somebody owning 100M shares. I know peregr said something similar to what you said.
"The Chapter 11 filing shows that there are 110M shares outstanding."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173569720
I did a half-ass look at some of the bankruptcy filing documents, but can find the reference to that OS.
It would be nice to get some clarification.
Every once in awhile, I'll read something here and wonder how someone can actually say what they said. You saying I'm wrong about what the company has accomplished in the past year, especially with the PREACH-M and RATinG Trials, is an example of a statement that I find incredulous.
But the top spot for incredulous statement comes from the SEC's Mission Statement, which I quoted in one of my posts. "As we continue to monitor the activities of more than 28,000 entities in the securities industry, we remain dedicated to the interests of long-term investors who are entrusting their hard-earned savings to our securities markets to fund home purchases, college educations, and other important life events."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173559584
In the linked post, talking about the SEC converting our recovered money to the government's use, how does that fulfill the SEC's Mission Statement? But most importantly, since this case relates to the NIAID, NIH, and FDA's willful negligence, which is. and will be, permitting millions of preventable deaths, the question becomes, 'What good does it do to protect the funding of life events, but to be negligent in preserving the lives of people who were funding those life events?'
The government's abuse of discretionary authority is intolerable, immoral, and in direct conflict with the very Mission Statement of the government.
I find it interesting that Novavax is projecting to gain market share in the US, while their mRNA competitors warn of reduced revenue expectations. I suspect that lenz is going to be responsible for the improved outlook for Novavax.
I think gone are the days when Humanigen was targeting a market size of 100K doses. If lenz can be used as a prophylaxis with the Novavax vaccine, we could be looking at a market for millions of doses of lenz.
I think even the therapeutic market for lenz will increase, if we don't have to wait for patients to progress to disease severity scale 4 for treatment. We can access patients with significantly lower CRP levels.
Humanigen and Novavax both filed 8-K's yesterday, with Item 7.01 Disclosures.
https://www.sec.gov/Archives/edgar/data/1293310/000121465924000421/0001214659-24-000421-index.htm
https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000110465924002100/tm242356d1_8k.htm
Our market cap was over $1B just in anticipation of the LIVE-AIR trial results, as I recall. The Class Action lawsuit amounts to reckless prosecution, and I expect Humanigen will counter-sue, and prevail in their suit. It appears to me that you are unaware of the basis for the Class Action Suit, which is so frivolous that it is absurd to think that we have to protect ourselves behind a bankruptcy in fear of this pathetic effort.
I wonder if Durrant will buy either the London or Dublin subsidiary, or, with a good chance of Regulatory Approval in Australia, maybe he'll buy that subsidiary.
https://www.humanigen.com/subsidiaries
Regardless, it appears that he may be buying the equity one of them.
I need to point out that there is an Item 7.01 Regulation FD Disclosure which states, "The Company expects that holders of shares of the Company’s common stock will experience a complete or significant loss on their investment, depending on the outcome of the Chapter 11 Case." We pretty much did that, already.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1293310/000121465924000421/o152468k.htm
However, a long range plan is in place for Taran (Durrant's Therapeutic company) to pay "...$20 million, comprised of $2 million in cash at closing of the Transaction and up to $18 million in milestone payments in cash..." spread out over a 5 - 7 year time frame. This obviously indicates that the company anticipates to survive as a going concern.
I'm pointing out what has been filed. But at the same time, I think the concern will prove moot, as it appears to me that we are prepared to repeat our history, and issue a second recall of our loaned shares.
Humanigen history lesson, for those who don't know it, or are too rattled to remember it.
"After the close of markets on November 18th (just one day after KBIO received its delisting notice), KBIO announced that an investor group led by Martin Shkreli had just acquired “more then 50%” of KBIO’s shares. So this is why the share price had spiked from 44 cents. When the market opened the next day, KBIO skyrocketed from $2.00 to over $14.00 on staggering volume, as terrified shorts scrambled for the exits...
After the close on November 19th, KBIO released a second announcement, stating that the group had now acquired a full 70% of outstanding shares and that Shkreli had been appointed as KBIO’s new CEO and Chairman. Shkreli’s group had stated that it would inject an initial $3 million in cash with an additional $10 million following shareholder approval. By November 23rd, KBIO had briefly hit $45 per share. But, even then Shkreli was not yet finished with his plan...
As KBIO’s share price had been spiking, short interest had been growing. And Shkreli now owned 70% of the outstanding shares. Then on Thanksgiving Day 2015, when markets were closed, Shkreli tweeted that he had decided to recall his KBIO shares that had been lent out to short sellers. The resulting squeeze was just a simple math problem. When Shkreli recalled his shares, brokers would be forced to buy-in the short sellers, causing it to spike uncontrollably."
https://moxreports.com/kbio-infinity-squeeze/
Things are not quite the same now, as they were then, when shares actually traded well above $200. I think Dale's entities are holding more than the 70% of shares as previously acquired. And of course, we have a successful Phase III LIVE-AIR trial, and outstanding results from the PREACH-M and RATinG trials, and an on-going trial of lenz for CAR-T sponsored by Mayo Clinic.
And let's not forget that our CEO is looking to invest millions more into Humanigen as our Debtor in Possession. I truly believe that we have never been stronger than we are now.
I blocked him, as well, so I am now back to one person blocked, when I prefer to have none. My own experience with corporate bankruptcy, working with, or as, the court-appointed Shareholders' Estate Representative, was the most empowering experience of my life.
Now, with Humanigen's bankruptcy filing, the SEC-related issues that have always plagued us, as they plagued SpongeTech, could potentially come into alignment, which would be disastrous for the SEC.
I hope Dale wins his Appeal, and shuts down any further litigation from the SEC.